title: Pancreatic safety of newer incretin-based therapies: are the "-tides" finally turning?
authors: Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX sxdevara@texaschildrens.org amaitra@mdanderson.org.
authors: Sridevi
authors: S
authors: Devaraj
authors: Departments of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX sxdevara@texaschildrens.org amaitra@mdanderson.org.
authors: Anirban
authors: A
authors: Maitra
mesh_terms: D000818:Animals; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000494:pharmacology; D004763:Glucagon-Like Peptides / Q000494:pharmacology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D000069450:Liraglutide; D008297:Male; D010179:Pancreas / Q000187:drug effects*; D000099194:Semaglutide
chemical_list: D052216:Glucagon-Like Peptide 1; D004763:Glucagon-Like Peptides; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D000099194:Semaglutide